Srinivas Akkaraju - 03 Sep 2025 Form 4 Insider Report for vTv Therapeutics Inc. (VTVT)

Reporting relationship: Director
Issuer ticker: VTVT
Reported as of: 03 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2025, 18:10:28 UTC
Prior SEC filing: 01 Aug 2025
Next SEC filing: 08 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Srinivas Akkaraju

Key filing fact

Srinivas Akkaraju filed Form 4 for vTv Therapeutics Inc. (VTVT) on 05 Sep 2025.

Key facts

This page summarizes Srinivas Akkaraju's Form 4 filing for vTv Therapeutics Inc. (VTVT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Sep 2025, 18:10.

Change

Previous filing in this sequence was filed on 01 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253170 Primary reporting owner

AKKARAJU SRINIVAS

Relationship: Director
Address: C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT
Signature: /s/ Srinivas Akkaraju
Signature date: 05 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTVT transaction Derivative

Pre-Funded Warrants (Right to Buy)

Award

Transaction value
Shares: +655,523
Change %: +73%
Price
Shares after: 1,548,101
Date: 03 Sep 2025
Ownership: Samsara BioCapital, L.P.
Underlying class: Class A Common Stock
Underlying amount: 655,523
Exercise price: $0.0100
Footnotes: F1, F2, F3

VTVT transaction Derivative

Warrant to Purchase Class A Common Stock (Right to Buy)

Award

Transaction value
Shares: +655,523
Change %
Price
Shares after: 655,523
Date: 03 Sep 2025
Ownership: By Samsara BioCapital, L.P.
Underlying class: Class A Common Stock
Underlying amount: 655,523
Exercise price: $22.71
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On August 29, 2025, Samsara BioCapital, L.P. ("Samsara LP") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock.

Footnote F2

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

Footnote F3

These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Footnote F4

The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.